| |
Investigational
HIV Vaccine (Major Pharmaceutical Co.)
A
study testing the safety, tolerability and effectiveness of
an investigational HIV-1 vaccine for the prevention of HIV/AIDS
transmission in healthy volunteers at high risk of HIV infection.
|
|
Currently
available HIV treatment has continued to allow important
improvements in quality of life and life expectancy
for HIV infected individuals. However, the virus continues
to spread around the world and there is a need to
find a vaccine stopping the spread of infection.
|
|
Objective
|
To
find out if this vaccine candidate is able to produce
immune responses in volunteers at high risk of HIV-1
infection from being infected by the virus.
Volunteers
cannot get HIV/AIDS from this experimental vaccine.
|
|
|
Volunteers
will be randomly assigned to either the vaccine group
or placebo.
|
Inclusion
Criteria
(partial
list)
|
•
Sexually active, male or female, aged 18-45
•
HIV-negative
and at high risk for HIV/AIDS infection
|
|
Status
__
|
Enrolling
--
|
For
more information about participating in this study
in the Los Angeles area, please call 310.358.2429
or e-mail Corie Castro at
ccastro@aidsresearch.org
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS ReSearch Alliance
Institutional Review Board in January, 2005.
|
|
